Results 11 to 20 of about 160,953 (345)
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report [PDF]
Journal of Hematology & Oncology, 2016 Background Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative in a variety of hematological malignancies. Graft-vs.-host disease (GvHD) remains a life-threatening complication.
Enrico Maffini +10 more
doaj +3 more sources
JAMA Oncol, 2023 Importance Chronic graft-vs-host disease (GVHD) limits the long-term benefit of haploidentical hematopoietic stem cell transplant (HSCT). This clinical trial evaluated repeated infusions of umbilical cord mesenchymal stem cells (MSCs) during the early ...
Huang R +14 more
europepmc +2 more sources
JAMA Netw Open, 2023 Key Points Question Are antibiotics and antibiotic exposure timeframes associated with acute graft-vs-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT)?
Rashidi A +7 more
europepmc +2 more sources
Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease
Frontiers in Immunology, 2019 Graft vs. host disease (GVHD) is the major non-relapse complication associated with allogeneic hematopoietic stem cell transplantation (HSCT). Damage to the gastrointestinal (GI) tract from acute GVHD is a particularly serious event that can result in ...
Clint Piper +2 more
doaj +2 more sources
Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance
Frontiers in Immunology, 2019 Graft-vs.-host disease (GVHD) remains a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Hongshuang Yu +5 more
doaj +2 more sources
Body Composition Assessment Provides Prognostic Information in Patients With Cancer Affected by Chronic Graft vs. Host Disease [PDF]
Journal of Cachexia, Sarcopenia and MuscleBackground Additional tools are needed to assess mortality risk among patients with cancer. Patients with chronic graft vs. host disease (cGVHD) after allogeneic haematopoietic cell transplantation (HCT) represent a high‐risk cancer population with ...
Asmita Mishra +8 more
doaj +2 more sources
Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease
Frontiers in Immunology, 2019 Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders.
Govindarajan Thangavelu, Bruce R. Blazar
doaj +2 more sources
Macrophage regulation of graft-vs-host disease
World Journal of Clinical Cases, 2020 Hematopoietic stem cell transplantation has become a curative choice of many hematopoietic malignancy, but graft-vs-host disease (GVHD) has limited the survival quality and overall survival of hematopoietic stem cell transplantation. Understanding of the immune cells' reaction in pathophysiology of GVHD has improved, but a review on the role of ...
Hong, Ya-Qun, Wan, Bo, Li, Xiao-Fan
openaire +3 more sources
The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease
Frontiers in Immunology, 2019 Allogeneic hematopoietic cell transplantation (allo-HCT) is performed with curative intent for high- risk blood cancers and bone marrow failure syndromes; yet the development of acute and chronic graft-vs.-host disease (GVHD) remain preeminent causes of ...
David Bastian +4 more
doaj +2 more sources
AAV-mediated expression of HLA-G for the prevention of experimental ocular graft vs. host disease [PDF]
Molecular Therapy: Methods & Clinical Development, 2023 Ocular graft versus host disease (OGvHD) develops after allogeneic hematopoietic stem cell transplantation (HSCT) and manifests as ocular surface inflammatory disease.
Jacob P. Nilles +8 more
doaj +2 more sources